Sector
PharmaceuticalsOpen
₹749.85Prev. Close
₹750.1Turnover(Lac.)
₹2,949.41Day's High
₹763.8Day's Low
₹742.5552 Week's High
₹860.2552 Week's Low
₹607.65Book Value
₹104.14Face Value
₹10Mkt Cap (₹ Cr.)
30,119.83P/E
64.64EPS
11.6Divi. Yield
0.1724 Apr 2024
12:00 AM
Dividend
Dividend Amount: 1.25
Record Date: 28 Jun, 2024
26 Apr 2023
12:00 AM
AGM
Announcement Date: 26 Apr, 2023
1 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 402 | 401.4 | 400.8 | 400 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,789.5 | 3,217.5 | 2,891.2 | 2,418.3 |
Net Worth | 4,191.5 | 3,618.9 | 3,292 | 2,818.3 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 2,601.4 | 2,179.4 | 2,011.9 | 1,423.1 |
yoy growth (%) | 19.36 | 8.32 | 41.37 | 18.5 |
Raw materials | -749 | -526.5 | -519.4 | -381.7 |
As % of sales | 28.79 | 24.15 | 25.81 | 26.82 |
Employee costs | -697.8 | -641.5 | -572.2 | -376.9 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 512.4 | 432.4 | 444.4 | 372.1 |
Depreciation | -309.7 | -274.5 | -219.3 | -131.4 |
Tax paid | -87.9 | -63.7 | -104.2 | -67 |
Working capital | -34.39 | 497.9 | -955.5 | 480.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.36 | 8.32 | 41.37 | 18.5 |
Op profit growth | 18.41 | 8.64 | 57.92 | 1.5 |
EBIT growth | 16.6 | -3.94 | 21.32 | 8.46 |
Net profit growth | -2.45 | -1.89 | 34.87 | 6.19 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 3,488.6 | 3,192.9 | 2,604.2 | 2,184.3 | 2,011.9 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,488.6 | 3,192.9 | 2,604.2 | 2,184.3 | 2,011.9 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 90.6 | 70.9 | 52.8 | 99.6 | 152.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Kiran Mazumdar Shaw
Non Executive Director
Catherine Patricia Rosenberg
Independent Director
Paul Frederick Blackburn
Independent Director
Vijay Kuchroo
Managing Director & CEO
Jonathan Hunt
Lead Independent Director
Vinita Bali
Company Sec. & Compli. Officer
Priyadarshnini Mahapatra
Independent Director
Sharmila Karve
Independent Director
Kush Parmar
Executive Director & CFO
SIBAJI BISWAS
Independent Director
Nilanjan Roy
Independent Director
Manja Boerman
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Syngene International Ltd
Summary
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising ~6000 scientists and its state-of-the-art facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore. The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited. The Companys health-related services extend across all major therapeutic areas and modalities. It provides end-to-end services within the Contract Research Organization (CRO) and a growing range of services within the Contract Development and Manufacturing Organization (CDMO). The primary target market for these services is the pharmaceutical and biotechnology (biotech) sectors. The same scientific capabilities that serve human health also serve nutrition, animal health, consumer goods, agri-chemicals, and specialty chemical sectors.Syngene International Limited was incorporated at Bangalore in the year 1993. During the year 1994-1995, the company pioneered in CRO services for both Chemistry and Biology. During the year 2001-2002, the company acquired a new facility inclusive o
Read More
What is the Syngene International Ltd share price today?
The Syngene International Ltd shares price on N/A is Rs.₹748.7 today.
What is the Market Cap of Syngene International Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Syngene International Ltd is ₹30137.94 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Syngene International Ltd?
The PE and PB ratios of Syngene International Ltd is 64.64 and 7.20 as of 22 Jul ‘24
What is the 52 Week High and Low of Syngene International Ltd?
The 52-week high/low is the highest and lowest price at which a Syngene International Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Syngene International Ltd is ₹608 and ₹860.2 as of 22 Jul ‘24
What is the CAGR of Syngene International Ltd?
Syngene International Ltd's CAGR for 5 Years at 18.68%, 3 Years at 3.87%, 1 Year at -2.59%, 6 Month at 7.81%, 3 Month at 5.12% and 1 Month at 5.51%.
What is the shareholding pattern of Syngene International Ltd?
The shareholding pattern of Syngene International Ltd is as follows:
Promoters - 54.72 %
Institutions - 37.43 %
Public - 7.42 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
